Temple

Temple operates within the health, wellness, and wearables sector, carving out a specialized niche in brain-centered performance monitoring rather than standard fitness tracking. Competing in a market alongside companies like Ultrahuman—which secured a $60 million funding round in September 2026—Temple differentiates itself by focusing specifically on cerebral blood flow, cognitive health, mental fatigue, and biomarker-driven metrics like the 'Entropy' energy expenditure score. Backed by prominent investors such as Vy Capital, Peak XV Partners, and Dharana Capital, and led by high-profile founder Deepinder Goyal, the company combines substantial early-stage financial backing with targeted acquisitions like Longevous to position itself at the intersection of consumer wearables and advanced longevity science.

Founded in early 2025 in New Delhi, India, Temple has experienced rapid growth characterized by significant capital raises and strategic talent acquisition. The company achieved a major inflection point in February 2026 by securing a $54 million seed funding round led by Deepinder Goyal, followed by a secondary market transaction in July 2026. Growth has accelerated through both organic milestones—such as the release of validation study results for its brain flow index and the launch of the Entropy metric in mid-2026—and inorganic expansion via the August 2026 acquisition of Longevous. With early access programs kicking off and limited-edition shipments slated for late 2026, the company is actively transitioning from a research-and-development startup into a commercial-stage neuro-performance hardware provider.